ImmunityBio Inc.

The novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp

The European Medicines Agency has begun reviewing for potential pan-EU marketing approval 10 new products, including depemokimab, GSK’s IL-5 inhibitor that could become the first ultra-long-acting dru

Many public biopharmaceutical companies have taken advantage of the ongoing capital markets recovery in 2024 by raising money through follow-on public offerings (FOPOs) after announcing key research a

Johnson & Johnson 's 2019 acquisition of privately held TARIS Biomedical LLC for an undisclosed sum is looking like a canny move after new data from early trials of its lead product, TAR-200, sugges